[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334244-105":59,"doc-detail-334244-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","splicemutr-enables-pan-cancer-analysis-of-splicing-derived-neoantigen-burden-in-tumors","SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors","","Aberrant alternative splicing can generate neoantigens that stimulate immune responses and surveillance. The paper introduces SpliceMutr, a bioinformatics pipeline that identifies splicing-derived neoantigens from tumor and normal data, detects tumor-specific splice variants, predicts MHC binding affinity, and computes splicing antigenicity scores. Applied to TCGA transcriptomes, it produces pan-cancer neoantigen sets and reveals correlations between splicing antigenicity and established antitumor immunity biomarkers. In melanoma cohorts, splicing antigen abundance decreases after progression on immune checkpoint inhibition, and increased antigenicity is observed in responders, supporting an immunotherapy-related role. The open pipeline enables further immuno-oncology analysis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/splicemutr-enables-pan-cancer-analysis-of-splicing-derived-neoantigen-burden-in-tumors/334244/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/splicemutr-enables-pan-cancer-analysis-of-splicing-derived-neoantigen-burden-in-tumors/334244.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does SpliceMutr address in neoantigen quantification?","Question",{"text":112,"@type":113},"It addresses limitations of prior methods, which rely on independent references and may be affected by batch effects when quantifying splicing-derived neoantigens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does SpliceMutr compute and predict from tumor and normal data?",{"text":117,"@type":113},"It identifies splicing-derived neoantigens, facilitates detection of tumor-specific antigenic splice variants, predicts MHC binding affinity, and estimates splicing antigenicity scores per gene.",{"name":119,"@type":110,"acceptedAnswer":120},"How is splicing antigenicity related to immune checkpoint inhibitor outcomes in the study?",{"text":121,"@type":113},"For melanoma patients treated with immune checkpoint inhibition, splicing antigen abundance decreases post-treatment in those who progress, while increased splicing antigenicity is observed in responders.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334244,1790808622,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0309](https://doi.org/10.1158/2767-9764.CRC-23-0309)  OPEN ACCESS  \nSpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors  \nTheron Palmer1,2, Michael D. Kessler2,3, Xiaoshan M. Shao1, Archana Balan1, Mark Yarchoan2,3,4, Neeha Zaidi2,3,4, Tamara Y. Lopez-Vidal2,3,4,5, Ali M. Saeed2,3,4, Jessica Gore7,8, Nilofer S. Azad2,3,4, Elizabeth M. Jaffee2,3,4, Alexander V. Favorov2,3,4,6, Valsamo Anagnostou3,4, Rachel Karchin1,3, Daria A. Gaykalova3,7,8, Elana J. Fertig1,2,3,4,9, and Ludmila Danilova2,3,4  \n􀀶  \nABSTRACT  \nAberrant alternative splicing can generate neoantigens, which can themselves stimulate immune responses and surveillance. Previous methods for quantifying splicing-derived neoantigens are limited by independent references and potential batch effects. Here, we introduce SpliceMutr, a bioinformatics approach and pipeline for identifying splicing-derived neoantigens from tumor and normal data. SpliceMutr facilitates the identification of tumor-specific antigenic splice variants, predicts MHCbinding affinity, and estimates splicing antigenicity scores per gene. By applying this tool to transcriptomic data from The Cancer Genome Atlas, we generate splicing-derived neoantigens and neoantigenicity scores per sample and across all cancer types and find numerous correlations between splicing antigenicity and well-established biomarkers of antitumor immunity. Notably, carriers of mutations within splicing machinery genes have higher splicing antigenicity, which provides support for our approach. Further analysis of splicing antigenicity in cohorts of patients with melanoma treated with mono- or combined immune checkpoint inhibition suggests that the abundance of splicing antigens is reduced post-treatment from baseline in patients who progress. We also observe increased splicing  \nantigenicity in responders to immunotherapy, which may relate to an increased capacity to mount an immune response to splicing-derived antigens. We find the splicing antigenicity to be higher in tumor samples when compared with normal, that mutations in the splicing machinery result in increased splicing antigenicity in some cancers, and higher splicing antigenicity is associated with positive response to immune checkpoint inhibitor therapies. Furthermore, this new computational pipeline provides novel analytical capabilities for splicing antigenicity and is openly available for further immuno-oncology analysis.  \nSignificance: SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load of some The Cancer Genome Atlas cancer subtypes. Future studies of the relationship between splicing antigenicity and immune checkpoint inhibitor response pan-cancer are essential to establish the interplay between antigen heterogeneity and immunotherapy regimen on patient response.  \n1Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland. 2Convergence Institute, Johns Hopkins University, Baltimore, Maryland. 3Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 4Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 5Biochemistry, Cellular and Molecular Biology (BCMB) Graduate Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6Laboratory of Systems Biology and Computational Genetics, Vavilov Institute of General Genetics, Moscow, Russia. 7Department of Otorhinolaryngology-Head and Neck Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland. 8Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland. 9Department of Ap","cbCaiow3l8pRFzSu","https://ap.wps.com/l/cbCaiow3l8pRFzSu","pdf",4534538,14,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What problem does SpliceMutr address in neoantigen quantification?\",\"answer\":\"It addresses limitations of prior methods, which rely on independent references and may be affected by batch effects when quantifying splicing-derived neoantigens.\"},{\"question\":\"What does SpliceMutr compute and predict from tumor and normal data?\",\"answer\":\"It identifies splicing-derived neoantigens, facilitates detection of tumor-specific antigenic splice variants, predicts MHC binding affinity, and estimates splicing antigenicity scores per gene.\"},{\"question\":\"How is splicing antigenicity related to immune checkpoint inhibitor outcomes in the study?\",\"answer\":\"For melanoma patients treated with immune checkpoint inhibition, splicing antigen abundance decreases post-treatment in those who progress, while increased splicing antigenicity is observed in responders.\"}]","SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors | PDF",1790005925,35]